KBI takes over Merck’s microbial process development and manufacturing.
KBI Biopharma, Inc. has signed an agreement with Merck & Co., Inc. (known as Merck in the United States and Canada) to acquire Merck’s microbial process development and manufacturing operations in Boulder, Colorado, effective May 1, 2014. Under the agreement, KBI will provide ongoing development and manufacturing services to Merck, as well as to third party customers.
“KBI will now offer expanded microbial development and manufacturing services up to 1500L scale, as well as continuing to offer our current full range of process development, analytical and formulation development and mammalian manufacturing services up to 2000L,” stated Joe McMahon, KBI’s President and CEO.
KBI will also continue to support other ongoing drug development programs for Merck from its two North Carolina facilities.
To date, KBI has helped to advance more than 220 molecules in 55 unique health indications for over 170 clients around the world.
Many facilities handle dangerous processes and products on a daily basis. Keeping everything under control demands well-trained people working with the best equipment.
Enhance the training experience and increase retention by training hands-on in Emerson's Interactive Plant Environment. Build skills here so you have them where and when it matters...
See how Rosemount™ 625IR Fixed Gas Detector helps keep workers safe with ultra-fast response times to detect hydrocarbon gases before they can create dangerous situations.
